Businesses in Singapore can be established as sole proprietorships, partnerships or companies with limited or unlimited liability, but early stage businesses seeking venture capital funding are in practice incorporated as private companies limited by shares. This gives investors a familiar corporate framework and limits each shareholder’s liability to the amount committed for their shares.

By statute, a private company limited by shares may have no more than 50 shareholders. For this purpose, employees who acquire shares through equity incentive plans while still employed are disregarded, but former employees who only receive shares after leaving the company are counted towards this 50-shareholder cap. To preserve headroom under this limit, some start ups route employee equity through a special purpose vehicle (SPV) or trust, and similar vehicles are sometimes used at later stages to pool smaller angel and SAFE investors into a single shareholder on the register.

If a private company exceeds the 50-shareholder threshold, it must convert into a public company and becomes subject to the more extensive Singapore statutory regime applicable to public companies. Where it has more than 50 shareholders and net tangible assets of at least S$5 million, the Singapore Code on Take overs and Mergers will also generally apply to changes of control.

The main documents in a typical venture capital equity round in Singapore are:

• Term sheet: A short-form document setting out the key commercial terms of the investment, usually expressed as non-binding other than confidentiality and, in most cases, exclusivity or no shop provisions.
• Share subscription agreement: The principal transaction document dealing with investment mechanics, including conditions precedent, warranties and completion arrangements.
• Disclosure letter: Sometimes called a schedule of exceptions, this qualifies the warranties in the subscription agreement by setting out specific disclosures against them.
• Shareholders’ agreement: Generally the most heavily negotiated document, governing the ongoing relationship between the shareholders and the company, including governance, information, transfer and economic rights.
• Constitution: The company’s constitutional document, which sets out, among other things, the rights attached to each class of shares and typically incorporates relevant agreed terms from the shareholders’ agreement.
• Board and shareholder resolutions: Corporate approvals authorising the transaction, including the issue of new shares, amendments to the constitution where required and the appointment of any new directors.

The constitution, certain board and shareholder resolutions and details of share issuances must be lodged with the Accounting and Corporate Regulatory Authority of Singapore (“ACRA”) and are generally available for public inspection on payment of a prescribed fee.

The Singapore Venture and Private Capital Association (“SVCA”) is the main industry body representing the interests of the venture and private capital community in Singapore. One of its key initiatives has been the development of the Venture Capital Investment Model Agreements (“VIMA”), a suite of Singapore-law model documents intended to provide a pragmatic starting point for early-stage financings.

VIMA 2.0 is used as a reference point for some pre-seed and seed rounds and can assist first-time founders and investors in managing costs and shortening negotiations by standardising core drafting on common issues. As companies mature and begin to raise larger rounds from regional or global investors, deal documentation typically moves away from the VIMA wording, with investors favouring bespoke terms and portfolio wide positions that reflect their own policies and the specific stage, structure and size of the transaction.

Singapore maintains an open, pro business regime with few economy-wide restrictions on foreign ownership, and most sectors have no specific foreign investment limits. Higher levels of foreign ownership in certain regulated industries, such as public utilities, land-related businesses and financial services, may trigger approval requirements, but there are no rules that treat venture capital as a distinct asset class for foreign investment purposes.

Merger control and competition matters are overseen by the Competition and Consumer Commission of Singapore (CCCS) under a voluntary merger notification regime. Transactions that may result in a substantial lessening of competition can be reviewed and, if necessary, remedial directions imposed, but minority venture investments will rarely approach the market share or control thresholds that would warrant closer scrutiny.

Singapore’s Significant Investments Review Act, which came into force on 28 March 2024, introduces a separate screening regime for investments in entities designated as critical to Singapore’s national security. Investors acquiring control or certain significant shareholding stakes in these “designated entities” (a closed list that is published and updated from time to time) must obtain approvals or make notifications to the Minister for Trade and Industry, but the current list covers nine large entities in the defence and energy/logistics space and is not expected to affect the vast majority of venture capital investments.

Internal approvals and process

A company may issue new shares only in accordance with its constitution, its shareholders’ agreement and the Singapore Companies Act 1967 (“Companies Act”). In a venture-backed company, new money rounds are typically treated as dilutive issuances that require approvals at board and shareholder level under negotiated reserved matters, with exceptions often carved out for issuances from an existing employee equity pool and other agreed “permitted” issuances. Depending on pricing, the company may also seek waivers of any anti dilution protections in favour of existing investors.

If a new class of shares is to be created, or if the rights of existing shares are to be varied, the constitution will usually need to be amended, which requires a special resolution passed by shareholders holding at least 75% of the voting shares and subsequent filing of the amended constitution with ACRA. Separately, section 161 of the Companies Act requires the board to obtain authority from shareholders, either by a specific mandate or a general mandate approved in general meeting, before exercising the power to issue shares. Such authority generally lasts until the conclusion of the next annual general meeting or the latest date by which that meeting must be held.

Taxes, notaries and filings

No stamp duty is payable on the issue of new shares in Singapore – stamp duty applies instead to transfers of existing shares. There is no requirement for notarial involvement in a primary issuance by a Singapore company, but the company (typically through its corporate secretary) must lodge the relevant board and shareholder resolutions, return of allotment (notice of issuance of shares) with ACRA within the prescribed timelines, which may attract modest filing fees.

Participation by non venture capital investors is a regular feature of the Singapore ecosystem, particularly from pre seed to Series B stages. Angels, family offices, corporate venture capital (“CVC”) and venture builders all play meaningful roles alongside traditional funds.

Angels and high net worth individuals: Angel investors and high net worth individuals often include friends and family as well as professional contacts of the founders, and they typically invest through SAFEs or similar convertible instruments. Angel networks and platforms – including those using roll-up vehicles (“RUVs”) – aggregate multiple smaller cheques into a single entity that can meet higher minimum allocations and, unlike individual angels, RUVs may participate in follow on rounds at higher valuations.

Family offices: Family offices are generally less likely to lead early-stage rounds directly, given broader portfolio mandates and limited in-house venture execution capacity. Instead, they more commonly co-invest alongside venture funds in which they are limited partners, using direct positions to increase exposure to selected companies or themes.

Corporate venture capital: Corporate venture capital arms of larger corporates remain a significant source of capital, often investing to gain access to technology, market intelligence and strategic options such as rights of first offer or refusal on commercial collaborations. Their relatively lower pressure to deliver a time-bound financial exit can be attractive to founders, although some companies are cautious about bringing in a CVC where it may signal alignment with a single incumbent competitor or complicate a cap table otherwise populated by financial investors with broadly similar fund lifecycles and exit expectations.

Venture builders and start up studios: Venture builders and start-up studios have a visible presence in Singapore, incubating technology, providing initial funding and operational support, and assembling experienced management teams. Their aim is typically to help portfolio companies reach product-market fit and initial commercial traction before those companies raise traditional institutional venture capital.

Historically, Singapore and regional venture funds have aimed to deploy most of their committed capital within roughly three to five years of final close and to manage exits on a seven to ten year horizon. These timelines are set at fund formation but, in practice, are heavily influenced by macroeconomic conditions, manager strategy and limited partner expectations.

In the immediate post-Covid period, many managers accelerated deployment as capital was abundant and valuations were buoyant, but since late 2022 that dynamic has largely reversed, with a material number of funds slowing or pausing new investments and redirecting reserves to extend runway for existing portfolio companies. Practically, the effective pace of new deals is now more measured, with a greater share of capital held back for follow-ons and structured solutions, longer due diligence cycles and a general preference for selectivity over forcing capital out into a more challenging market, even as fund lives run down.

Venture investors in Singapore typically receive preference shares, which carry both economic protections and voting rights, with a new class often created for each equity financing round. Certain rights – such as information rights, pre emption, rights of first refusal and tag along rights – are often limited to “major investors” that hold at least a specified fully diluted stake.

Key terms that venture investors typically look for include:

• Anti dilution protection: Conversion price adjustments that protect investors against down rounds by increasing the number of ordinary shares into which their preference shares convert.
• Liquidation preferences: Priority rights on a liquidation, sale or winding up, often entitling preference shareholders to recover some or all of their investment ahead of ordinary shareholders and, in some cases, earlier series.
• Board representation and observers: Appointment rights for lead investors to nominate at least one director (and sometimes an observer), usually conditional on maintaining an agreed minimum shareholding.
• Information rights: Regular delivery of financial statements, management accounts, budgets and business plans to designated investors, sometimes coupled with enhanced inspection and audit rights.
• Pre emption / pro rata rights: Rights for certain investors to participate in future issuances to maintain, and in some cases increase, their fully diluted ownership.
• Rights of first refusal / first offer and tag along rights: Rights to purchase, or to participate in, proposed sales of shares by other shareholders, typically founders or early employees.
• Drag along rights: Rights for a specified shareholder majority to compel minority shareholders to join in an exit, including a sale of the company or change of control.
• Board and shareholder reserved matters: Lists of actions, for example changes to share capital, major acquisitions or disposals, or related-party transactions, that require supermajority board and/or investor approvals.
• Exit rights: Provisions such as demand or piggyback registration rights for an IPO, redemption or put rights in defined default scenarios, and covenants for the company to use reasonable or best efforts to pursue an exit within an agreed timeframe.
• Transfer restrictions and founder terms: Vesting, lock ups and good/bad leaver provisions, usually applied more strictly to founders and key management than to venture investors.

At a documentation level, investors will expect a comprehensive suite of representations and warranties from the company, usually backed by a negotiated indemnity. In earlier stage rounds it remains common for founders to give a narrower set of personal representations and warranties, often focused on title to shares and fraud or wilful misconduct carve-outs.

In practice, the liability regime in Singapore venture deals for share subscriptions is largely monetary: breaches of representations and warranties are typically addressed through damages under the subscription agreement, subject to agreed limitations of liability. By contrast, breaches of ongoing obligations under the shareholders’ agreement – for example, governance, information, transfer and other protective provisions – are generally pursued through damages, with investors also able to seek equitable remedies such as specific performance and injunctions where appropriate.

It is relatively unusual for start-ups, particularly at seed and Series A, to appoint a financial adviser to run a formal process or broker a round, and most venture investors will resist any part of their investment being used to pay third-party success or finder’s fees. Companies are often required to give a warranty in the subscription agreement that no such fees are payable at closing.

By contrast, it is standard for the lead investor – and occasionally existing investors providing follow on capital – to ask for reimbursement of out of pocket legal and due diligence costs, subject to an agreed cap. That cap is typically calibrated by reference to factors such as: (i) the complexity and jurisdictional spread of the corporate group, (ii) whether the business operates in a regulated sector that requires specialist regulatory or compliance work, and (iii) the structure of the round, including any anti dilution implications, multiple key investors, staggered or tranched closings, parallel secondary sales or performance linked valuation mechanics.

Restrictive covenants for founders and senior management are common, but they need to be tightly drafted to be enforceable. Non-compete provisions are typically used to protect the company’s legitimate business interests and must be reasonable in scope, duration and, where relevant, geography and closely connected to the company’s actual business to be upheld by the courts. They are often paired with non solicitation covenants restricting dealings with customers, suppliers and employees.

For founders and other key personnel, non-compete and non-solicit obligations will generally apply both during their engagement with the company and for a defined period following cessation of employment or a material reduction in their shareholding, with post-termination restricted periods of around 6 to 24 months being common. For founders, these obligations are usually reflected both in the shareholders’ agreement and in their employment or service agreements. For rank-and-file employees, any non-compete typically runs for a defined period following cessation of employment, whereas for founders and significant employee shareholders, the post-exit restricted period may only start once their equity falls below a specified threshold and, in more stringent structures, only after they have fully exited their shareholding.

Employees in venture backed companies in Singapore are most often incentivised through time-vested founder equity and employee share option plans. Founder equity is typically issued at incorporation, with investors expecting it to vest over a number of years rather than being fully owned from day one. A common structure for both founders and employees is a four-year vesting period with a one-year cliff and monthly vesting thereafter, with other employees generally granted options on the same or a similar schedule.

As founders and key employees are diluted in later funding rounds, they may receive “top up” equity awards, which can vest by reference to time, milestones or key performance indicators. As a matter of market practice, options are generally preferred to issuing ordinary shares directly: in many jurisdictions, including Singapore, tax on options generally arises on exercise, whereas tax on restricted shares generally arises on vesting, and under Singapore law ordinary share buybacks are capped at 20% of the outstanding ordinary shares between annual general meetings, which can make it more difficult for a company to buy back large blocks of unvested ordinary shares when an employee departs.

Employee option plans may also include acceleration features. Under a “single-trigger” structure, some or all unvested options vest automatically upon a liquidity event such as a sale of the company, whereas under a “double-trigger” structure, unvested options accelerate only where there is both a liquidity event and a qualifying termination of the founder or key employee (typically other than for cause) within an agreed period, with the latter more commonly applied to senior management as it balances exit participation with ongoing retention incentives.

Founders and senior management are usually subject to fairly detailed vesting and leaver mechanics, with economic outcomes tied to the circumstances of departure. Investors commonly require the shareholders’ agreement to define “good leaver” and “bad leaver” outcomes and to link those outcomes to share buy-back or transfer rights over founder and management equity.

A “bad leaver” is typically someone dismissed for cause (for example, serious misconduct or fraud) or who resigns without good reason, and the precise definitions of “cause” and “good reason” are often among the most heavily negotiated provisions given their direct personal impact. In a bad leaver scenario, the company, and sometimes other investors, will usually have the right to acquire some or all of the bad leaver’s vested equity at nominal value or at a discount to fair value, with fair value often determined by an independent valuation or by reference to a percentage of the latest preference share price. By contrast, a good leaver’s vested equity may either be left untouched or, if subject to a purchase right, is more commonly acquired at prevailing fair value, and in both good and bad leaver cases unvested equity is typically subject to compulsory buy-back or forfeiture at nominal value, usually framed as being subject to statutory buy-back limits and the company’s ability to meet applicable solvency requirements.

Valuation and dilution

The funding reset that began in late 2022 continued through 2023 and 2024 and still shapes deal terms going into 2025 to 2026. Deal activity in Southeast Asia remains well below 2021 to 2022 levels, and investors are cautious about backing high growth plans without a clear route to monetisation and capital efficiency, so valuation and dilution remain heavily negotiated. Investors are seeking mechanisms to re-price economics if performance falls short, while founders are looking for ways to regain value after accepting down or structured rounds.

To bridge valuation gaps, companies are increasingly using structured rounds that embed performance-linked economics, such as:

• Conversion price adjustments tied to milestones and key performance indicators, where the conversion ratio adjusts in favour of the investor if targets are missed.
• Management equity pools that function like earn-outs, allowing key management to claw back some dilution on achieving key performance indicators or exit outcomes.
• Staggered or tranched closings, giving investors the option to deploy capital over 12 to 18 months once more data is available.
• In some later-stage deals, fair market value put options if an exit has not occurred by an agreed date.

Internal controls, governance and founder liability

A series of governance incidents and misreporting concerns across the region has kept investor attention firmly on internal controls and accountability, and this has carried into 2025. Investors are focused not only on what is promised in the documentation but also on who stands behind those promises, and on self-executing protections that can adjust economics without lengthy enforcement processes.

Key themes include:

• Founder exposure for fraud, wilful misconduct and, in some cases, gross negligence, with these carve outs sitting outside general limitation regimes.
• Greater reliance on “self executing” protections – for example, conversion price adjustments or additional share issuances that automatically adjust economics if key representations or financial metrics prove inaccurate – rather than relying solely on cash indemnities.
• More extensive founder undertakings and personal covenants around internal controls, policy compliance, disclosure of related-party transactions and cooperation with information and audit rights, with breach feeding into bad-leaver treatment.
• A more active approach to information rights, with investors insisting on detailed, regular financial reporting and reserving the right to obtain data to run their own internal analysis, particularly for higher-risk jurisdictions or more complex business models.
• Increasingly granular and contested drafting around exit decision making thresholds, as investors seek greater influence over the timing and form of liquidity events while founders look to preserve a meaningful say.
• A broader and more detailed list of board and shareholder reserved matters, especially for financial reporting, capital structure changes, significant transactions and related party dealings.

SAFEs remain a very common form of convertible instrument for pre‑seed and early seed rounds in Singapore, particularly for founders prioritising speed and low transaction costs. Convertible notes are more frequently used as bridge instruments once a company has completed at least one priced equity round or where investors want the additional structure and protections that come with debt.

Convertible notes are at times preferred by investors because they can be put in place quickly, typically within a few weeks, and generally do not require amendments to the shareholders’ agreement or constitution or any filings with ACRA until conversion. They rank ahead of equity in a liquidation or insolvency scenario and their terms are usually personal to the noteholder, so other investors cannot unilaterally waive or vary them, and notes also allow parties to defer a full valuation exercise, particularly where they convert on a discount‑to‑next‑round basis or at the more favourable of a discount or valuation cap.

Companies should be mindful that convertible notes, even if unsecured and mandatorily convertible outside of a default or maturity event, are generally accounted for as debt, which can increase reported leverage and the cost of borrowing. Until they convert, notes also sit ahead of equity in the capital structure, and in practice it can be difficult to attract new equity investors into a company with a significant overhang of outstanding convertible debt.

SAFEs in Singapore generally follow the Y Combinator standard form (adapted for use by Singapore companies). Convertible notes, by contrast, do not have a single prevailing template; while there is a VIMA 2.0 form, market practice continues to draw on a variety of base precedents.

A typical SAFE provides for automatic conversion into preferred shares on the occurrence of the next equity financing, usually at either (i) a discount to the price per share in that round, (ii) a post‑money valuation cap, or (iii) the more favourable of the two. In a liquidity event prior to a qualifying financing, SAFE holders will typically have the option either to convert into the most senior class of equity then outstanding or to receive a return of their purchase amount in priority to ordinary shareholders, generally ranking pari passu with other SAFEs and preferred shares, and because the YC‑style SAFE is structured on a post‑money basis it is broadly non‑dilutive to the new round investors and other SAFEs, with the dilution borne by the existing shareholders at the time of issue.

Convertible notes operate on a similar conceptual basis, in that they typically convert on a qualified equity financing using a discount, valuation cap or both, but they rank ahead of all equity in a liquidation or insolvency scenario and accrue interest. Beyond the conversion mechanics, commonly negotiated note terms include maturity (repayment date or mandatory conversion/redemption), financial and operational covenants, noteholder consent rights over reserved matters, default remedies including acceleration and, where applicable, enforcement of security, most‑favoured‑nation protection for later note terms and, in some cases, warrants issued alongside the notes as an economic “kicker”.

Over the last 24 months, debt products have remained an important alternative or supplement to equity for Singapore and regional start ups. Venture debt facilities from specialist venture lenders and certain banks are typically used to extend runway or fund growth initiatives while reducing incremental dilution.

As companies mature, a broader range of options opens up, including larger and more structured growth debt and private credit solutions offered by dedicated funds and bank platforms. Founders and investors often view these instruments as less dilutive than a traditional priced equity round but are increasingly focused on debt service, covenant intensity and the constraints that senior or secured debt can place on future fundraising and exit flexibility.

Venture and growth stage debt terms vary by lender and borrower profile, but a number of points are commonly negotiated.

• Maturity: Venture debt is typically shorter-dated, with maturity periods in the one to three year range and, in many cases, an initial period during which only interest is payable before principal repayments increase, whereas more traditional growth or bank debt often has longer tenors and a wider range of repayment profiles.
• Interest and repayment: Because borrowers are earlier-stage and higher-risk, venture debt generally carries a higher coupon than mainstream bank debt but remains cheaper than unsecured mezzanine capital, while growth and bank debt is usually priced off a benchmark rate plus a margin and venture debt is more often set at a fixed or floating rate agreed deal-by-deal.
• Collateral package: Venture and growth debt are commonly secured by a first-ranking charge over key assets, which can include intellectual property, bank accounts, receivables and shares in material subsidiaries, and where the borrower is a subsidiary, guarantees or co borrowing from the parent and operating entities are common.
• Covenants: Growth debt facilities typically impose more extensive financial and operational covenants, including leverage and coverage ratios and restrictions on additional indebtedness or disposals, while venture debt covenants tend to be somewhat lighter, focusing on minimum cash, liquidity or revenue thresholds and information undertakings, although covenant intensity generally increases with facility size and borrower maturity.
• Fees and penalties: Upfront arrangement or commitment fees, as well as prepayment and default fees, are standard on growth facilities, and venture debt may include similar features but, particularly at earlier stages, fee structures are often simpler and negotiated on a case-by-case basis.
• Equity “kickers”: Venture debt is frequently accompanied by warrants or similar equity linked instruments, giving the lender the right to acquire ordinary or preferred shares at a negotiated price or at a discount to a future equity round. Growth debt may also incorporate equity-linked upside (for example, warrants or performance linked fees) as a negotiated point.

Funding activity in Singapore and Southeast Asia remains below 2021–2022 peaks but has stabilised around more disciplined pricing, structures and governance expectations rather than a broad resurgence in risk appetite. Venture investors are placing greater emphasis on demonstrable product–market fit, recurring or repeatable revenues and a credible path to breakeven, and due diligence processes have lengthened as they scrutinise internal reporting, controls and fraud risk more closely, with sectors such as AI, fintech and deeptech themes attracting relatively more attention. Over the next 12 months, deployment is expected to increase gradually as funds balance support for existing portfolio companies with the need to deploy remaining dry powder within their investment periods.

Exits and capital recycling are a central focus for regional funds, many of which are now in their mid‑ to late‑life, with earlier “paper” uplifts having partially normalised. General partners are correspondingly more active in pursuing liquidity through secondary sales, GP‑led continuation vehicles and similar structures, and trade sales, with the most visible exits continuing to be strategic acquisitions rather than IPOs, including sales to larger U.S. and global platforms acquiring teams and products in sectors such as AI and fintech. In parallel, Singapore is deepening its pipeline in capital‑intensive sectors such as biotech, deeptech and medtech, including through expanded public co‑investment programmes and other initiatives aimed at strengthening later‑stage funding and eventual exit pathways.

No major legislative reforms are currently expected that would directly and materially alter the core legal framework for venture capital investments in Singapore over the next 12 months. The key developments are policy and programme‑driven, and focus on deeptech, growth capital and exit pathways.

First, Startup SG Equity (SSGE), a Singapore government scheme to support Singapore‑based early‑stage deeptech start‑ups, will be significantly expanded, with S$1 billion set aside to top up the scheme. Through SSGE, the government co‑invests alongside qualified private investors into early‑stage deeptech start‑ups, makes direct investments into selected growth‑stage deeptech companies and commits capital to VC firms with the capability and track record to support later‑stage deeptech growth.

Second, a Growth Capital Workgroup has been convened, chaired at ministerial level and comprising senior public and private‑sector stakeholders. Its terms of reference focus on strengthening the full value chain of growth capital – enhancing Singapore’s capabilities in deal origination, capital raising and mobilisation, and capital recycling – so that private capital can be raised, retained and compounded in Singapore as regional enterprises scale.

Third, the Monetary Authority of Singapore and Singapore Exchange Regulation have proposed the establishment of a new SGX Global Listing Board and associated legislative changes to operationalise an SGX–Nasdaq dual‑listing bridge. The proposed framework would provide a streamlined pathway for eligible Nasdaq Global Select Market issuers to obtain a concurrent Singapore listing, with harmonised admission, disclosure and reporting standards, with the aim of attracting larger high‑growth Asian companies to raise capital in both markets and broadening eventual exit options for venture‑backed companies.